



Synthesis of topsentolides A₂ and C₂, and non-enzymatic conversion of the former to the latter



Ryo Towada, Shigefumi Kuwahara *

Laboratory of Applied Bioorganic Chemistry, Graduate School of Agricultural Science, Tohoku University, Tsutsumidori-Amamiyamachi, Aoba-ku, Sendai 981-8555, Japan

ARTICLE INFO

Article history:

Received 22 March 2014

Received in revised form 9 April 2014

Accepted 11 April 2014

Available online 18 April 2014

Keywords:

Topsentolide

Oxylipin

Cytotoxic

Artifact

Marine natural product

ABSTRACT

The first total synthesis of the marine-derived cytotoxin topsentolide A₂, which eventually culminated in its stereochemical determination, was accomplished in 17 steps from a known chiral alcohol. An improved synthesis of its congener, topsentolide C₂, from a synthetic intermediate of topsentolide A₂ was also performed by utilizing the Yamaguchi lactonization to construct its nine-membered lactone ring. Treatment of epoxide ring-containing topsentolide A₂ with HCl/MeOH brought about its quantitative conversion into topsentolide C₂.

© 2014 Elsevier Ltd. All rights reserved.

1. Introduction

In the search for cytotoxic substances from the marine sponge *Topsentia* sp., Jung and co-workers isolated seven oxylipins containing a nine-membered lactone ring and named them topsentolides A₁, A₂, B₁–B₃, C₁, and C₂.^{1,2} The marine natural products were all shown to exhibit significant cytotoxicity against five human solid tumor cell lines with ED₅₀ values of 2.4–17.5 µg/mL. The planar structures of the topsentolides were determined based on extensive spectroscopic analyses, while their stereochemistry was not assigned conclusively except for the relative configuration between the C11 and C12 stereogenic centers of topsentolides A₁, A₂, and B₁–B₃ as well as the absolute configuration at the hydroxy-bearing C12 position of topsentolide C₂, which was determined to be *S* by the modified Mosher method (see compound **2** in Fig. 1).¹ The naturally rare nine-membered lactone unit embedded in common in the topsentolides and their medicinally important biological activity attracted considerable attention from organic chemists, and thereby six synthetic studies on topsentolides have been reported so far.^{3–7} Among them, the one reported by Watanabe and co-workers led to the determination of the absolute stereochemistry of topsentolide A₁ as 8*R*, 11*R*, and 12*S* (structure **1**, Fig. 1) by comparison of the ¹H NMR spectra and specific rotations of two synthetic stereoisomers of topsentolide A₁ with those of




Fig. 1. Absolute configuration of topsentolides A₁ (**1**) and C₂ (**2**), and assumed stereochemistry of topsentolide A₂ (**3**).

natural topsentolide A₁.³ We also conducted a stereodivergent synthesis of all of the four diastereomers of topsentolide C₂ bearing a methoxy group at the C11 position and established its stereochemistry as 8*R*, 11*S*, and 12*S* (structure **2**).⁷

As part of our ongoing efforts toward the total synthesis of bioactive oxylipins,^{7,8} we set about the first synthesis and stereochemical determination of topsentolide A₂ (17,18-dihydro derivative of **1**). Although the stereochemistry of topsentolide A₂ was not established by Jung et al. except for the relative configuration of the epoxide ring moiety as *cis*, we tentatively assumed its


* Corresponding author. Tel./fax: +81 22 717 8783; e-mail address: skuwahar@biochem.tohoku.ac.jp (S. Kuwahara).

stereochemistry to be 8*R*, 11*R*, and 12*S* as depicted in **3** based on their speculation that topsentolide C₂ (**2**) might be an artifact derived non-enzymatically from topsentolide A₂ during the extraction of the latter with MeOH from the marine sponge as well as by analogy to the absolute configuration of topsentolide A₁ (**1**).³ We describe herein the total synthesis of the tentative structure of topsentolide A₂ (**3**), determination of the stereochemistry of topsentolide A₂, improved synthesis of topsentolide C₂ (**2**), and non-enzymatic conversion of **3** into **2**.

2. Results and discussion

2.1. Retrosynthetic analysis of **2** and **3**

Scheme 1 delineates our retrosynthetic analysis of topsentolides C₂ (**2**) and A₂ (**3**) that features the use of appropriately protected seco acid **4** as a common precursor. The nine-membered lactone ring contained in **2** and **3** would be installable by the Yamaguchi lactonization of a seco acid intermediate generated by deprotection of the methyl ester and TBS ether functionalities of **4**, while the epoxide ring in **3** would be constructed by properly manipulating the oxygen-containing functional groups at the C11 and C12 positions. With a view to establishing the *E*-geometry at the C9–C10 double bond of **4** by the Horner–Wadsworth–Emmons olefination, the pivotal intermediate **4** was traced back to two building blocks **5** and **6**. The aldehyde **5** would readily be accessible from known alcohol **7**, and the phosphonate **6** via the Evans asymmetric alkylation of oxazolidinone derivative **8** with allylic iodide **9**.




Scheme 1. Retrosynthetic analysis of **2** and **3**.

2.2. Preparation of aldehyde **5**

The preparation of the aldehyde segment **5** is depicted in Scheme 2.⁹ The starting alcohol **7**, which was prepared from *D*-malic acid in two steps according to the literature procedure,¹⁰ was converted into phosphonium salt **10b** via iodide **10a** in 83% yield for the two steps. The Wittig olefination of **10b** with methyl 5-oxopentanoate proceeded in a highly *Z*-selective manner, affording **11** in 73% yield. Acidic hydrolysis of its acetal protecting group with Amberlite IR-120 Plus¹¹ followed by bis-TBS etherification of


the resulting diol **12a** afforded **12b** almost quantitatively from **11**. Treatment of **12b** with HF·Py effected selective unmasking of the primary hydroxy group,¹² furnishing **12c** (70% yield), which, on exposure to the Swern oxidation conditions, afforded the aldehyde **5** quantitatively.



Scheme 2. Preparation of aldehyde **5**. Reagents and conditions: (a) I₂, Ph₃P, imidazole, CH₂Cl₂; (b) Ph₃P, MeCN, 83% from **7**; (c) NaHMDS, methyl 5-oxopentanoate, THF, 73%; (d) Amberlite IR-120 Plus, MeOH/H₂O; (e) TBSCl, imidazole, DMF, 99% from **11**; (f) HF·Py, THF/Py, 70%; (g) DMSO, (COCl)₂, Et₃N, CH₂Cl₂, quant.

2.3. Preparation of phosphonate **6**

The preparation of the phosphonate segment **6** commenced with the Evans asymmetric alkylation of **8**^{8b,13} with iodide **9**^{8b,14} to give **13** in 73% yield after chromatographic purification (Scheme 3).¹⁵ The *N*-acyl oxazolidinone **13** was hydrolyzed with aq LiOH and the resulting carboxylic acid **14a** was converted into the corresponding Weinreb's amide **14b** in 80% yield over the two steps. Finally, treatment of **14b** with dimethyl lithiomethylphosphonate gave **6** in 94% yield.




Scheme 3. Preparation of phosphonate **6**. Reagents and conditions: (a) NaHMDS, THF, 73%; (b) LiOH·H₂O, H₂O₂, THF/H₂O; (c) MeNH(OMe)·HCl, DCC, DMAP, CH₂Cl₂, 80% from **13**; (d) MePO(OMe)₂, *n*-BuLi, THF, 94%.

2.4. Synthesis of topsentolide C₂

With the two building blocks, **5** and **6**, in hand, we proceeded to their connection followed by transformation of the resulting product into topsentolide C₂ (**2**) (Scheme 4). The *E*-selective Horner–Wadsworth–Emmons reaction between **5** and **6** under the Roush–Masamune conditions gave an 85% yield of enone **15**,¹⁶ which was then subjected to Luche's reduction conditions, delivering Felkin–Ahn product **4** as a single diastereomer in 98% yield.^{8b} O-Methylation of **4** was efficiently performed by its treatment with NaHMDS and MeI in HMPA/THF and exposure of the resulting product **16a** to TBAF in THF furnished alcohol **16b** in 80% yield for the two steps. Saponification of the methyl ester **16b** with aq LiOH gave seco acid **17** almost quantitatively, which set the stage for the Yamaguchi lactonization to install the nine-membered


lactone ring.¹⁷ The ring forming reaction of **17** was effected in an excellent yield of 95%, and subsequent removal of the PMB protecting group of the cyclization product **18** gave topsentolide C₂ (**2**) quantitatively. The ¹H and ¹³C NMR spectra of **2** were identical with those of natural topsentolide C₂ and, of course, with those of our synthetic sample of **2** previously obtained in a lower overall yield due to poor efficiency (56% yield) in the Mitsunobu lactonization employed for the formation of the lactone ring.⁷ The specific rotation value of **2** {[α]_D²¹ +77.2 (c 0.820, MeOH)} showed good agreement with our previous data {[α]_D²⁹ +86.8 (c 1.33, MeOH)}.⁷



Scheme 4. Synthesis of **2**. Reagents and conditions: (a) Et₃N, LiBr, THF, 80%; (b) NaBH₄, CeCl₃·7H₂O, MeOH, 98%; (c) NaHMDS, MeI, HMPA, THF, 82%; (d) TBAF, THF, 98%; (e) LiOH·H₂O, THF/H₂O, 99%; (f) Cl₃C₆H₂COCl, DIPEA, THF, then DMAP, toluene, 95%; (g) DDQ, CH₂Cl₂/H₂O, 99%.

2.5. Synthesis of topsentolide A₂

Scheme 5 outlines the transformation of the intermediate **4** into the tentative structure of topsentolide A₂ (**3**). Protection of the alcohol **4** as its 1-ethoxyethyl ether followed by deprotection of the TBS group of the resulting product **19a** afforded hydroxy ester **19b**, which was then subjected to basic hydrolysis conditions, providing seco acid **19c** (94% yield from **4**) as a mixture of diastereomers due to the newly formed stereocenter in the EE group. Lactonization of **19c** under the Yamaguchi conditions furnished nine-membered lactone derivative **20a** in 88% yield. Removal of the EE group of **20a** with PPTS in EtOH and subsequent mesylation of alcohol intermediate **20b** gave **20c**. Treatment of the PMB ether **20c** with DDQ in CH₂Cl₂/phosphate buffer (pH 7) afforded a very unstable hydroxy mesylate **20d**, which was, after quick purification by silica gel column chromatography to remove *p*-methoxybenzaldehyde generated as a by-product, exposed to K₂CO₃ in MeOH, providing epoxy lactone **3**, albeit in a modest overall yield of 16% for the four steps (mainly due to the instability of **20d**). The ¹H and ¹³C NMR spectral data of **3** were identical with those reported for natural topsentolide A₂,¹ and the specific rotation of **3** {[α]_D²¹ +73 (c 0.22, MeOH)} was in good accord with that of natural topsentolide A₂ {[α]_D²⁴ +84.6 (c 0.27, MeOH)}.¹ Based on these results as well as by analogy to the stereochemistry of topsentolide A₁ (**1**), we



Scheme 5. Synthesis of **3**. Reagents and conditions: (a) EtOCH=CH₂, PPTS, CH₂Cl₂; (b) TBAF, THF; (c) LiOH·H₂O, THF/H₂O, 94% from **4**; (d) Cl₃C₆H₂COCl, DIPEA, THF, then DMAP, toluene, 88%; (e) PPTS, EtOH; (f) Ms₂O, DIPEA, DMAP, CH₂Cl₂; (g) DDQ, CH₂Cl₂/phosphate buffer (pH 7); (h) K₂CO₃, MeOH, 16% from **20a**.


concluded that the absolute configuration of topsentolide A₂ should be represented by structure **3**.

2.6. Methanolytic epoxide ring-opening of **3** into **2** under acidic conditions

To demonstrate the speculation by Jung and co-workers that topsentolide C₂ (**2**) might be an artifact derived non-enzymatically from topsentolide A₂ (**3**) during the extraction of **3** from *Topsentia* sp. with MeOH,¹ we tried exposing **3** to a mixture of MeOH and CH₂Cl₂ at room temperature; both the solvents were employed in their extraction process. Under these neutral conditions, compound **3** was quite stable and did not change at all after 3 h of stirring. On the other hand, refluxing the solution of **3** in MeOH/CH₂Cl₂ brought about gradual decomposition of **3** and finally led to its disappearance and the formation of a mixture of unidentified products after overnight stirring, none of which was found to be identical with topsentolide C₂ (**2**) by TLC analysis. Quite interestingly, however, treatment of **3** with hydrogen chloride in MeOH at room temperature for a few hours effected complete consumption of **3** and generated topsentolide C₂ (**2**) almost quantitatively with inversion of configuration at the allylic C11 position (see Supplementary data for the NMR spectra of the crude reaction product) (Scheme 6).¹⁸ These results would support the above-mentioned speculation by Jung et al. that topsentolide C₂ (**2**) might be an artifact formed from topsentolide A₂ (**3**), although, at present, we have no way of knowing whether their sponge extract was acidic or not.

3. Conclusion

In conclusion, the first total synthesis of topsentolide A₂ (**3**) was accomplished in 4.4% overall yield from the known alcohol **7** by a 17-step sequence (or 5.7% yield from the allylic iodide **9** through 14 steps) involving the Evans asymmetric alkylation as a source of chirality and the highly diastereoselective reduction of the α-alkoxy ketone to install the C12 stereogenic center. We also achieved an improved synthesis of topsentolide C₂ (**2**) by exploiting the Yamaguchi lactonization for the formation of the nine-membered lactone ring instead of the Mitsunobu lactonization previously employed in our first synthesis of **2**. Treatment of **3** with



Scheme 6. Methanolysis of epoxide ring-opening of **3** into **2**.

methanolic HCl brought about methanolysis opening of the epoxide ring at the C11 allylic position with inversion of configuration and afforded **2** quantitatively, which supported the speculation by Jung et al. that topsentolide C₂ (**2**) might be an artifact derived from topsentolide A₂ (**3**).

4. Experimental section

4.1. General

IR spectra were recorded by a Jasco FT/IR-4100 spectrometer using an ATR (ZnSe) attachment. ¹H NMR spectra were recorded with TMS as an internal standard in CDCl₃ by a Varian MR-400 spectrometer (400 MHz) unless otherwise stated. ¹³C NMR were recorded in CDCl₃ by the same spectrometer (100 MHz) and chemical shifts were reported with reference to the solvent peak (CDCl₃, 77.16 ppm) unless otherwise stated. Optical rotation values were measured with a Horiba Septa-300 polarimeter, and the mass spectra were obtained with Jeol JMS-700 spectrometer operated in the EI or FAB mode. Merck silica gel 60 (70–230 mesh) was used for column chromatography. Solvents for reactions were distilled prior to use: THF from Na and benzophenone; CH₂Cl₂, MeCN, DMF, and HMPA from CaH₂; MeOH from Mg(OMe)₂; toluene from LiAlH₄; EtOH from Na and diethyl phthalate. All air- or moisture-sensitive reactions were conducted under a nitrogen atmosphere.

4.2. Methyl (Z)-7-[(R)-2,2-diethyl-1,3-dioxolan-4-yl]-5-heptenoate (**11**)

To a stirred solution of **7** (5.78 g, 33.2 mmol) in CH₂Cl₂ (150 mL) were successively added imidazole (6.82 g, 100.0 mmol), Ph₃P (11.5 g, 43.8 mmol), and I₂ (10.8 g, 42.6 mmol) at 0 °C. The resulting mixture was gradually warmed to room temperature and stirred overnight. The mixture was quenched with saturated aq Na₂S₂O₃ and extracted with hexane. The extract was washed with brine, dried (MgSO₄), and concentrated in vacuo to give crude **10a** (8.40 g), which was taken up in MeCN (100 mL). To the solution was added Ph₃P (9.34 g, 35.6 mmol) while stirring at room temperature, and the mixture was then heated under reflux for 17 h. The mixture was cooled to room temperature and concentrated in vacuo to give a solid, which was suspended in Et₂O and filtered to give **10b** (15.0 g, 83% from **7**). To a stirred suspension of **10b** (2.44 g, 4.46 mmol) in THF (10 mL) was added dropwise a solution of NaHMDS (1.0 M in THF, 6.70 mL, 6.70 mmol) at 0 °C, and the resulting solution was stirred at the same temperature for 1 h. To the solution was added dropwise a solution of methyl 5-oxopentanoate (700 mg, 5.35 mmol) in THF (5 mL) at –78 °C. After 3 h, the mixture was gradually warmed to room temperature, stirred overnight, and then quenched with saturated aq NH₄Cl. The

mixture was concentrated in vacuo and filtered. The filtrate was extracted with hexane/EtOAc (4:1), and the extract was washed with brine, dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc=10:1) to give **11** (880 mg, 73%) as a pale yellow oil. [α]_D²⁵ –23.0 (c 1.06, CHCl₃); IR: ν_{\max} 3015 (w), 1738 (s), 1160 (m), 1077 (m); ¹H NMR: δ 0.89 (3H, t, *J*=7.4 Hz), 0.91 (3H, t, *J*=7.4 Hz), 1.58–1.75 (6H, m), 2.10 (2H, q, *J*=7.2 Hz), 2.22–2.29 (1H, m), 2.32 (2H, t, *J*=7.6 Hz), 2.38–2.47 (1H, m), 3.50 (1H, dd, *J*=7.6, 6.5 Hz), 3.67 (3H, s), 4.04 (1H, dd, *J*=7.6, 6.5 Hz), 4.10 (1H, quint, *J*=6.5 Hz), 5.37–5.53 (2H, m); ¹³C NMR: δ 8.14, 8.40, 24.8, 26.9, 29.8, 30.0, 31.5, 33.6, 51.7, 69.8, 75.9, 113.0, 125.3, 131.5, 174.2; HRMS (FAB): *m/z* calcd for C₁₅H₂₇O₄ ([M+H]⁺) 271.1909, found 271.1910.

4.3. Methyl (5Z,8R)-8,9-bis[(*tert*-butyldimethylsilyl)oxy]-5-nonenoate (**12b**)

To a stirred solution of **11** (650 mg, 2.40 mmol) in MeOH/H₂O (20:1, 8.4 mL) was added Amberlite IR-120 Plus (500 mg) at room temperature. After 15 h, the mixture was filtered and the filtrate was concentrated in vacuo. The residue was diluted with Et₂O, dried (Na₂SO₄), and concentrated in vacuo to give crude **12a** (480 mg), which was taken up in DMF (5 mL). To the solution were successively added imidazole (975 mg, 14.3 mmol) and TBSCl (1.09 g, 7.23 mmol) at 0 °C. After 12 h, the mixture was quenched with H₂O at 0 °C and extracted with EtOAc. The extract was washed with brine, dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc=50:1) to give **12b** (1.02 g, 99% from **11**) as a pale yellow oil. [α]_D²³ +1.73 (c 1.42, CHCl₃); IR: ν_{\max} 3014 (w), 1742 (s), 1252 (m), 1098 (m), 832 (s); ¹H NMR: δ 0.04 (6H, s), 0.05 (6H, s), 0.88 (9H, s), 0.89 (9H, s), 1.69 (2H, quint, *J*=7.5 Hz), 2.08 (2H, q, *J*=7.5 Hz), 2.11–2.19 (1H, m), 2.26–2.34 (1H, m), 2.31 (2H, t, *J*=7.7 Hz), 3.41 (1H, dd, *J*=10.0, 6.3 Hz), 3.49 (1H, dd, *J*=10.0, 5.5 Hz), 3.64–3.71 (4H, m), 5.37–5.52 (2H, m); ¹³C NMR: δ –5.22, –5.16, –4.5, –4.2, 18.3, 18.5, 25.0, 26.0 (3C), 26.1 (3C), 26.9, 32.3, 33.7, 51.6, 67.1, 73.3, 127.1, 130.3, 174.3; HRMS (FAB): *m/z* calcd for C₂₂H₄₆O₄Si₂Na ([M+Na]⁺) 453.2833, found 453.2837.

4.4. Methyl (5Z,8R)-8-[(*tert*-butyldimethylsilyl)oxy]-9-hydroxy-5-nonenoate (**12c**)

To a solution of **12b** (418 mg, 0.970 mmol) in THF (5 mL) was added dropwise a solution of HF·Py (40% HF·Py/Py/THF=1:2:5, 4.0 mL) at –10 °C. After 24 h, the mixture was quenched with saturated aq NaHCO₃ and extracted with Et₂O. The extract was successively washed with saturated aq CuSO₄ and brine, dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc=50:1–4:1) to give **12c** (215 mg, 70%) as a yellow oil. [α]_D²⁴ –17.5 (c 1.06, CHCl₃); IR: ν_{\max} 3477 (m), 1739 (s), 834 (s), 775 (s); ¹H NMR: δ 0.09 (6H, s), 0.90 (9H, s), 1.69 (2H, quint, *J*=7.4 Hz), 1.90 (1H, t, *J*=6.3 Hz), 2.08 (2H, q, *J*=7.4 Hz), 2.19–2.29 (2H, m), 2.32 (2H, t, *J*=7.4 Hz), 3.40–3.47 (1H, m), 3.51–3.58 (1H, m), 3.67 (3H, s), 3.72–3.79 (1H, m), 5.36–5.49 (2H, m); ¹³C NMR: δ –4.5, –4.3, 18.2, 24.9, 26.0 (3C), 26.8, 32.1, 33.6, 51.7, 66.0, 72.8, 126.0, 131.1, 174.2; HRMS (FAB): *m/z* calcd for C₁₆H₃₃O₄Si ([M+H]⁺) 317.2148, found 317.2152.

4.5. Methyl (5Z,8R)-8-[(*tert*-butyldimethylsilyl)oxy]-9-oxo-5-nonenoate (**5**)

To a stirred solution of (COCl)₂ (0.130 mL, 1.58 mmol) in CH₂Cl₂ (2.6 mL) was added dropwise a solution of DMSO (0.220 mL, 3.15 mmol) in CH₂Cl₂ (4 mL) at –78 °C. After 5 min, a solution of **12c** (400 mg, 1.26 mmol) in CH₂Cl₂ (2.5 mL) was added and the resulting mixture was stirred at –78 °C for 30 min. To the mixture

was added dropwise Et₃N (0.880 mL, 6.30 mmol) and the mixture was gradually warmed to –30 °C. The mixture was quenched with saturated aq NaHCO₃, gradually warmed to room temperature, and extracted with CH₂Cl₂. The extract was washed with brine, dried (Na₂SO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc=10:1) to give **5** (400 mg, quant) as a pale yellow oil. [α]_D²² +13.4 (c 1.04, CHCl₃); IR: ν_{max} 3020 (w), 1738 (s), 1252 (m), 836 (m), 777 (m); ¹H NMR: δ 0.07 (3H, s), 0.09 (3H, s), 0.92 (9H, s), 1.69 (2H, quint, *J*=7.5 Hz), 2.03–2.13 (2H, m), 2.31 (2H, t, *J*=7.5 Hz), 2.39 (2H, t, *J*=6.4 Hz), 3.67 (3H, s), 4.00 (1H, dt, *J*=1.3, 6.4 Hz), 5.40–5.53 (2H, m), 9.60 (1H, d, *J*=1.3 Hz); ¹³C NMR: δ –4.7, –4.6, 18.3, 24.8, 25.9 (3C), 26.8, 31.0, 33.6, 51.7, 77.6, 124.6, 131.9, 174.1, 204.0; HRMS (FAB): *m/z* calcd for C₁₆H₃₁O₄Si ([M+H]⁺) 315.1992, found 315.1994.

4.6. (*R*)-4-Benzyl-3-[(2*S*,4*Z*)-2-(4-methoxyphenyl)methoxy-4-decenoyl]-2-oxazolidinone (**13**)

To a stirred solution of NaHMDS (1.0 M in THF, 7.60 mL, 7.60 mmol) in THF (10 mL) was added dropwise a solution of **8** (1.80 g, 5.06 mmol) in THF (15 mL) at –78 °C. After 30 min, a solution of **9** (2.86 g, 12.0 mmol) in THF (10 mL) was added and the resulting mixture was stirred at –78 °C for 30 min. The mixture was gradually warmed to –40 °C and stirred overnight. The mixture was quenched with saturated aq NH₄Cl and extracted with Et₂O. The extract was washed with brine, dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc=4:1) to give **13** (1.72 g, 73%) as a colorless oil. [α]_D²⁴ –71.2 (c 0.960, CHCl₃); IR: ν_{max} 1778 (s), 1708 (m), 1612 (w), 1513 (m), 1248 (s); ¹H NMR: δ 0.87 (3H, t, *J*=7.1 Hz), 1.22–1.38 (6H, m), 2.05 (2H, q, *J*=6.8 Hz), 2.48–2.65 (2H, m), 2.70 (1H, dd, *J*=13.3, 9.6 Hz), 3.23 (1H, dd, *J*=13.3, 3.2 Hz), 3.79 (3H, s), 4.12–4.18 (2H, m), 4.48 (1H, d, *J*=11.2 Hz), 4.53 (1H, d, *J*=11.2 Hz), 4.55–4.63 (1H, m), 5.12 (1H, dd, *J*=7.0, 5.2 Hz), 5.44–5.57 (2H, m), 6.86 (2H, d, *J*=8.6 Hz), 7.19 (2H, d, *J*=6.8 Hz), 7.24–7.35 (5H, m); ¹³C NMR: δ 14.2, 22.7, 27.5, 29.4, 31.1, 31.6, 38.0, 55.1, 55.4, 66.8, 72.5, 76.6, 113.8 (2C), 123.5, 127.5, 129.1 (2C), 129.6 (2C), 129.8, 130.1 (2C), 133.5, 135.2, 153.1, 159.5, 172.8; HRMS (FAB): *m/z* calcd for C₂₈H₃₅NO₅Na ([M+Na]⁺) 488.2413, found 488.2413.

4.7. (2*S*,4*Z*)-*N*-Methoxy-2-(4-methoxyphenyl)methoxy-*N*-methyl-4-decenamide (**14b**)

To a stirred solution of **13** (0.320 g, 0.687 mmol) in THF/H₂O (3:1, 12 mL) were successively added 30% aq H₂O₂ (0.270 g, 2.35 mmol) and LiOH·H₂O (60.4 mg, 1.44 mmol) at 0 °C. After 3 h, the mixture was quenched with 1.5 M aq Na₂SO₃ and gradually warmed to room temperature over 2 h. The mixture was concentrated in vacuo, and the residue was diluted with saturated aq NaHCO₃ and extracted with Et₂O. The aqueous layer was acidified with 2 M aq HCl and extracted with CH₂Cl₂. The extract was washed with brine, dried (MgSO₄), and concentrated in vacuo to give crude **14a** (197 mg), which was taken up in CH₂Cl₂ (4 mL). To the solution were successively added MeNH(OMe)·HCl (94.2 mg, 96.6 mmol), DMAP (118 mg, 96.7 mmol), and DCC (199 mg, 96.7 mmol) while stirring at 0 °C. The mixture was gradually warmed to room temperature over 3 h and filtered through a pad of Celite. The filtrate was successively washed with saturated aq NH₄Cl, saturated NaHCO₃, and brine, dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc=5:1) to give **14b** (192 mg, 80% from **13**) as a yellow oil. [α]_D²⁴ –53.4 (c 1.00, CHCl₃); IR: ν_{max} 1672 (s), 1613 (m), 1513 (s), 1247 (s); ¹H NMR: δ 0.87 (3H, t, *J*=7.0 Hz), 1.20–1.36 (6H, m), 2.01 (2H, q, *J*=6.9 Hz), 2.46–2.52 (2H, m), 3.21 (3H, s), 3.57 (3H, s), 3.80 (3H, s), 4.28 (1H, br t, *J*=5.5 Hz), 4.35 (1H, d, *J*=11.7 Hz), 4.62 (1H, d, *J*=11.7 Hz), 5.39–5.53 (2H, m), 6.86 (2H, d, *J*=8.6 Hz), 7.28 (2H, d, *J*=8.6 Hz); ¹³C

NMR: δ 13.9, 22.4, 27.1, 29.1, 30.2, 31.3, 32.1, 55.0, 61.1, 70.9, 74.8, 113.5 (2C), 124.0, 129.4 (2C), 129.7, 132.5, 159.1, 172.7; HRMS (FAB): *m/z* calcd for C₂₀H₃₂NO₄ ([M+H]⁺) 350.2331, found 350.2329.

4.8. Dimethyl [(3*S*,5*Z*)-3-(4-methoxyphenyl)methoxy-2-oxo-5-undecenyl]phosphonate (**6**)

To a stirred solution of MePO(OMe)₂ (2.0 mL, 18.7 mmol) in THF (110 mL) was added dropwise a solution of *n*-BuLi (1.59 M in hexane, 11.0 mL, 17.5 mmol) at –78 °C. After 1 h, a solution of **14b** (1.27 g, 3.63 mmol) in THF (30 mL) was added, and the resulting mixture was stirred at –78 °C for 6 h. The mixture was quenched with saturated aq NH₄Cl, gradually warmed to room temperature, and extracted with EtOAc. The extract was washed with brine, dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc=1:1) to give **6** (1.41 g, 94%). [α]_D²³ –19.7 (c 1.00, CHCl₃); IR: ν_{max} 1720 (w), 1612 (w), 1514 (m), 1248 (s), 1027 (s); ¹H NMR: δ 0.88 (3H, t, *J*=6.8 Hz), 1.21–1.37 (6H, m), 2.00 (2H, q, *J*=7.2 Hz), 2.38–2.53 (2H, m), 3.16 (1H, dd, *J*=21.8, 14.7 Hz), 3.32 (1H, dd, *J*=21.8, 14.7 Hz), 3.76 (3H, d, *J*=5.9 Hz), 3.79 (3H, d, *J*=5.9 Hz), 3.81 (3H, s), 3.96 (1H, t, *J*=6.0 Hz), 4.46 (1H, d, *J*=11.1 Hz), 4.57 (1H, d, *J*=11.1 Hz), 5.35 (1H, dt, *J*=10.8, 7.2 Hz), 5.51 (1H, dt, *J*=10.8, 7.2 Hz), 6.88 (2H, d, *J*=8.6 Hz), 7.28 (2H, d, *J*=8.6 Hz); ¹³C NMR: δ 14.2, 22.7, 27.5, 29.3, 29.6, 31.6, 36.3 (d, *J*=132.4 Hz), 53.1 (2C), 55.4, 72.4, 84.2, 114.0 (2C), 123.3, 129.6, 129.8 (2C), 133.6, 159.6, 204.1 (d, *J*=7.5 Hz); HRMS (FAB): *m/z* calcd for C₂₁H₃₄O₆P ([M+H]⁺) 413.2093, found 413.2093.

4.9. Methyl (5*Z*,8*R*,9*E*,12*S*,14*Z*)-8-(*tert*-butyldimethylsilyl)oxy-12-(4-methoxyphenyl)methoxy-11-oxo-5,9,14-icosatrienoate (**15**)

A mixture of **6** (576 mg, 1.40 mmol) and LiBr (243 mg, 2.80 mmol) in THF (14 mL) was stirred at room temperature for 30 min. To the mixture was added Et₃N (0.260 mL, 1.90 mmol) and the mixture was stirred for 1 h. Then a solution of **5** (400 mg, 1.27 mmol) in THF (12 mL) was added, and the resulting mixture was stirred overnight at room temperature. The mixture was quenched with saturated aq NH₄Cl and extracted with Et₂O. The extract was washed with brine, dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc=10:1 to 1:1) to give **15** (668 mg, 80%) as a pale yellow oil. [α]_D²² –37.0 (c 1.10, CHCl₃); IR: ν_{max} 1739 (s), 1696 (w), 1630 (w), 1514 (m), 1249 (s); ¹H NMR: δ 0.03 (3H, s), 0.06 (3H, s), 0.87 (3H, t, *J*=7.0 Hz), 0.90 (9H, s), 1.20–1.35 (6H, m), 1.68 (2H, quint, *J*=7.4 Hz), 1.98 (2H, q, *J*=7.4 Hz), 2.05 (2H, q, *J*=6.9 Hz), 2.23–2.36 (4H, m), 2.36–2.50 (2H, m), 3.66 (3H, s), 3.80 (3H, s), 3.92 (1H, t, *J*=6.6 Hz), 4.32 (1H, d, *J*=11.5 Hz), 4.32–4.37 (1H, m), 4.53 (1H, d, *J*=11.5 Hz), 5.31–5.52 (4H, m), 6.69 (1H, dd, *J*=15.6, 1.3 Hz), 6.86 (2H, d, *J*=8.6 Hz), 6.99 (1H, dd, *J*=15.6, 4.4 Hz), 7.24 (2H, d, *J*=8.6 Hz); ¹³C NMR: δ –4.7, –4.5, 14.2, 18.3, 22.7, 24.8, 25.9 (3C), 26.9, 27.5, 29.3, 30.5, 31.6, 33.6, 35.5, 51.6, 55.4, 71.8, 72.0, 83.8, 113.9 (2C), 123.2, 123.5, 125.5, 129.5 (2C), 129.8, 131.4, 133.2, 150.1, 159.4, 174.1, 201.0; HRMS (FAB): *m/z* calcd for C₃₅H₅₆O₆SiNa ([M+Na]⁺) 623.3743, found 623.3741.

4.10. Methyl (5*Z*,8*R*,9*E*,11*S*,12*S*,14*Z*)-8-(*tert*-butyldimethylsilyl)oxy-11-hydroxy-12-(4-methoxyphenyl)methoxy-5,9,14-icosatrienoate (**4**)

A mixture of **15** (145 mg, 0.241 mmol) and CeCl₃·7H₂O (98.2 mg, 0.264 mmol) in MeOH (4 mL) was stirred at room temperature for 5 min. To the mixture was added dropwise a solution of NaBH₄ (9.03 mg, 0.239 mmol) in MeOH (0.8 mL) at –78 °C and the resulting mixture was stirred for 1 h. The mixture was quenched with saturated aq NH₄Cl, gradually warmed to room temperature,

and extracted with Et₂O. The extract was washed with brine, dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc=10:1–4:1) to give **4** (142 mg, 98%) as a pale yellow oil. $[\alpha]_D^{25} +3.45$ (c 1.00, CHCl₃); IR: ν_{\max} 3529 (w), 3006 (w), 1739 (m), 1613 (w), 1513 (m), 1248 (s); ¹H NMR: δ 0.03 (3H, s), 0.05 (3H, s), 0.86–0.91 (12H, m), 1.22–1.39 (6H, m), 1.68 (2H, quint, $J=7.5$ Hz), 1.97–2.10 (4H, m), 2.17–2.34 (5H, m), 2.36–2.44 (1H, m), 2.56 (1H, br s, OH), 3.33 (1H, q, $J=5.6$ Hz), 3.66 (3H, s), 3.80 (3H, s), 4.04 (1H, br s), 4.11–4.19 (1H, m), 4.45 (1H, d, $J=11.0$ Hz), 4.62 (1H, d, $J=11.0$ Hz), 5.37–5.53 (4H, m), 5.64 (1H, dd, $J=15.3$, 6.2 Hz), 5.76 (1H, dd, $J=15.3$, 5.3 Hz), 6.87 (2H, d, $J=8.2$ Hz), 7.25 (2H, d, $J=8.2$ Hz); ¹³C NMR: δ –4.6, –4.2, 14.2, 18.4, 22.7, 24.9, 26.0 (3C), 26.9, 27.6, 28.5, 29.4, 31.7, 33.6, 36.4, 51.6, 55.4, 72.3, 72.6, 73.5, 82.2, 114.0 (2C), 124.7, 126.7, 128.8, 129.6 (2C), 130.5 (2C), 132.6, 135.9, 159.4, 174.2; HRMS (FAB): m/z calcd for C₃₅H₅₈O₆SiNa ([M+Na]⁺) 625.3901, found 625.3896.

4.11. Methyl (5Z,8R,9E,11S,12S,14Z)-8-(*tert*-Butyldimethylsilyl)oxy-11-methoxy-12-(4-methoxyphenyl)methoxy-5,9,14-icosatrienoate (**16a**)

To a stirred solution of **4** (142 mg, 0.236 mmol) and HMPA (0.140 mL, 0.826 mmol) in THF (2.4 mL) was added dropwise a solution of NaHMDS (1.0 M in THF, 0.230 mL, 0.230 mmol) at –78 °C. After 1 h, MeI (0.23 mL, 0.230 mmol) was added, and the resulting mixture was stirred at –78 °C for 5 h. The mixture was gradually warmed to room temperature and stirred overnight. The mixture was quenched with saturated aq NH₄Cl and extracted with Et₂O. The extract was washed with brine, dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc=10:1 to 4:1) to give **16a** (119 mg, 82%) as a colorless oil. $[\alpha]_D^{20} -7.72$ (c 0.950, CHCl₃); IR: ν_{\max} 3008 (w), 1740 (s), 1613 (w), 1514 (m), 1248 (s), 1081 (s); ¹H NMR: δ 0.04 (3H, s), 0.06 (3H, s), 0.88 (3H, t, $J=7.3$ Hz), 0.89 (9H, s), 1.20–1.37 (6H, m), 1.67 (2H, quint, $J=7.4$ Hz), 1.96–2.09 (4H, m), 2.13–2.24 (2H, m), 2.24–2.39 (4H, m), 3.28 (3H, s), 3.33–3.39 (1H, m), 3.60 (1H, dd, $J=7.6$, 5.1 Hz), 3.66 (3H, s), 3.79 (3H, s), 4.16 (1H, q, $J=5.8$ Hz), 4.52 (1H, d, $J=11.4$ Hz), 4.59 (1H, d, $J=11.4$ Hz), 5.34–5.49 (4H, m), 5.55 (1H, dd, $J=15.7$, 7.6 Hz), 5.66 (1H, dd, $J=15.7$, 5.8 Hz), 6.85 (2H, d, $J=8.3$ Hz), 7.26 (2H, d, $J=8.3$ Hz); ¹³C NMR: δ –4.6, –4.3, 14.2, 18.3, 22.7, 24.9, 26.0 (3C), 26.9, 27.5, 28.9, 29.4, 31.7, 33.6, 36.4, 51.6, 55.4, 56.8, 72.7, 72.9, 81.4, 83.9, 113.7 (2C), 125.7, 126.6, 127.2, 129.5 (2C), 130.4, 131.2, 132.1, 137.7, 159.1, 174.1; HRMS (FAB): m/z calcd for C₃₆H₆₀O₆SiNa ([M+Na]⁺) 639.4057, found 639.4053.

4.12. (5Z,8R,9E,11S,12S,14Z)-8-Hydroxy-11-methoxy-12-(4-methoxyphenyl)methoxy-5,9,14-icosatrienoate (**16b**)

TBS ether **16a** (97.4 mg, 0.158 mmol) and a solution of TBAF (1.0M in THF, 0.470 mL, 0.470 mmol) was mixed at 0 °C, and the mixture was stirred at the same temperature for 30 min. The mixture was warmed to room temperature and stirred for an additional 3 h. The mixture was quenched with saturated aq NH₄Cl and extracted with Et₂O. The extract was washed with brine, dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc=2:1) to give **16b** (78.0 mg, 98%) as a colorless oil. $[\alpha]_D^{20} +4.17$ (c 1.27, CHCl₃); IR: ν_{\max} 3459 (m), 3006 (w), 1737 (s), 1613 (m), 1514 (s), 1247 (s); ¹H NMR: δ 0.88 (3H, t, $J=6.6$ Hz), 1.21–1.38 (6H, m), 1.70 (2H, quint, $J=7.4$ Hz), 1.77 (1H, d, $J=3.9$ Hz, OH), 2.01 (2H, q, $J=6.8$ Hz), 2.09 (2H, q, $J=7.2$ Hz), 2.16–2.26 (1H, m), 2.26–2.42 (5H, m), 3.29 (3H, s), 3.34–3.41 (1H, m), 3.63 (1H, dd, $J=7.2$, 4.9 Hz), 3.66 (3H, s), 3.79 (3H, s), 4.14–4.22 (1H, m), 4.55 (2H, s), 5.35–5.56 (4H, m), 5.64 (1H, dd, $J=15.5$, 7.2 Hz), 5.73 (1H, dd, $J=15.5$, 5.5 Hz), 6.85 (2H, d, $J=8.4$ Hz), 7.26 (2H, d, $J=8.4$ Hz); ¹³C NMR: δ 14.2, 22.7, 24.8, 26.8, 27.5, 28.7, 29.4, 31.7, 33.5, 35.4, 51.7, 55.4, 57.0, 71.7, 72.6, 81.0, 83.3,

113.7 (2C), 125.6, 125.8, 128.2, 129.7 (2C), 131.0, 132.1, 132.2, 136.4, 159.2, 174.2; HRMS (FAB): m/z calcd for C₃₀H₄₆O₆Na ([M+Na]⁺) 525.3192, found 525.3191.

4.13. (5Z,8R,9E,11S,12S,14Z)-8-Hydroxy-11-methoxy-12-(4-methoxyphenyl)methoxy-5,9,14-icosatrienoic acid (**17**)

To a stirred mixture of **16b** (78.0 mg, 0.155 mmol) in THF/H₂O (3:1, 2 mL) was added LiOH·H₂O (64.5 mg, 1.54 mmol) at room temperature and the resulting mixture was stirred at 40 °C for 16 h. The mixture was cooled to room temperature, quenched with 1 M oxalic acid, and extracted with CH₂Cl₂. The extract was washed with brine, dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc=1:1) to give **17** (75.2 mg, 99%) as a colorless oil. $[\alpha]_D^{19} +5.50$ (c 1.07, CHCl₃); IR: ν_{\max} 3397 (m), 3005 (m), 1709 (s), 1614 (w), 1514 (s), 1248 (s); ¹H NMR: δ 0.88 (3H, t, $J=6.7$ Hz), 1.20–1.38 (6H, m), 1.70 (2H, quint, $J=7.1$ Hz), 2.01 (2H, q, $J=6.7$ Hz), 2.11 (2H, q, $J=7.1$ Hz), 2.17–2.26 (1H, m), 2.26–2.42 (5H, m), 3.29 (3H, s), 3.39 (1H, q, $J=5.7$ Hz), 3.63 (1H, dd, $J=6.6$, 4.9 Hz), 3.79 (3H, s), 4.18 (1H, q, $J=5.7$ Hz), 4.53 (1H, d, $J=11.7$ Hz), 4.56 (1H, d, $J=11.7$ Hz), 5.34–5.56 (4H, m), 5.64 (1H, dd, $J=15.6$, 7.2 Hz), 5.73 (1H, dd, $J=15.6$, 5.4 Hz), 6.85 (2H, d, $J=8.3$ Hz), 7.26 (2H, d, $J=8.3$ Hz); ¹³C NMR: δ 14.2, 22.7, 24.6, 26.7, 27.5, 28.7, 29.4, 31.7, 33.4, 35.3, 55.4, 57.0, 71.8, 72.5, 81.0, 83.2, 113.7 (2C), 125.6, 125.9, 128.1, 129.7 (2C), 130.9, 131.9, 132.2, 136.4, 159.2, 178.8; HRMS (FAB): m/z calcd for C₂₉H₄₄O₆Na ([M+Na]⁺) 511.3036, found 511.3038.

4.14. (6Z,9R)-4,5,8,9-Tetrahydro-9-[(1E,3S,4S,6Z)-3-methoxy-4-(4-methoxyphenyl)methoxy-1,6-dodecadienyl]-2(3H)-oxoninone (**18**)

To a stirred solution of **17** (57.5 mg, 0.118 mmol) and DIPEA (145 μ L, 0.833 mmol) in THF (2.4 mL) was added 2,4,6-trichlorobenzoyl chloride (92.0 μ L, 0.589 mmol) at 0 °C. After 30 min, the mixture was warmed to room temperature and stirred for 1.5 h. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was diluted with toluene (8 mL) and added dropwise to a solution of DMAP (360 mg, 2.95 mmol) in toluene (100 mL) at 90 °C over 8 h. After being stirred at 90 °C for an additional 1 h, the mixture was cooled to room temperature and diluted with EtOAc. The resulting solution was successively washed with 0.5 M aq HCl, saturated aq NaHCO₃, and brine, dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc=10:1) to give **18** (52.7 mg, 95%) as a colorless oil. $[\alpha]_D^{19} +57.0$ (c 1.40, CHCl₃); IR: ν_{\max} 3009 (w), 1740 (s), 1612 (w), 1513 (m), 1247 (m), 1079 (s); ¹H NMR: δ 0.88 (3H, t, $J=6.7$ Hz), 1.20–1.38 (6H, m), 1.75–1.86 (1H, m), 1.97–2.13 (5H, m), 2.18–2.55 (6H, m), 3.30 (3H, s), 3.37 (1H, q, $J=5.7$ Hz), 3.60–3.65 (1H, m), 3.79 (3H, s), 4.53 (1H, d, $J=11.6$ Hz), 4.58 (1H, d, $J=11.6$ Hz), 5.29 (1H, br d, $J=10.8$ Hz), 5.35–5.56 (4H, m), 5.69–5.79 (2H, m), 6.85 (2H, d, $J=8.4$ Hz), 7.26 (2H, d, $J=8.4$ Hz); ¹³C NMR: δ 14.2, 22.7, 25.4, 26.6, 27.5, 28.6, 29.4, 31.7, 33.6, 34.6, 55.4, 57.1, 72.36, 72.42, 80.7, 83.0, 113.7 (2C), 124.5, 125.4, 129.5, 129.7 (2C), 130.9, 131.7, 132.3, 135.2, 159.2, 173.9; HRMS (FAB): m/z calcd for C₂₉H₄₂O₅Na ([M+Na]⁺) 493.2929, found 493.2928.

4.15. (6Z,9R)-4,5,8,9-Tetrahydro-9-[(1E,3S,4S,6Z)-4-hydroxy-3-methoxy-1,6-dodecadienyl]-2(3H)-oxoninone (**2**)

To a stirred mixture of **18** (50.0 mg, 0.106 mmol) in CH₂Cl₂/H₂O (10:1, 1.1 mL) was added DDQ (72.3 mg, 0.319 mmol) at 0 °C. After 2 h, the mixture was quenched with saturated aq NaHCO₃ and extracted with CH₂Cl₂. The extract was washed with brine, dried (MgSO₄), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc=4:1) to give **2**

(36.7 mg, 99%) as a colorless oil. $[\alpha]_D^{25} +77.2$ (c 0.820, MeOH); IR: ν_{\max} 3476 (m), 3012 (m), 1742 (s), 1138 (m), 1080 (m); ^1H NMR (CD_3OD): δ 0.90 (3H, t, $J=6.6$ Hz), 1.24–1.40 (7H, m), 1.70–1.83 (1H, m), 1.99–2.25 (7H, m), 2.29–2.58 (4H, m), 3.29 (3H, s), 3.47–3.53 (2H, m), 5.24–5.30 (1H, m), 5.41–5.53 (4H, m), 5.69 (1H, dd, $J=15.6$, 7.4 Hz), 5.86 (1H, dd, $J=15.6$, 5.4 Hz); ^{13}C NMR (CD_3OD , δ 49.00 ppm): δ 14.4, 23.6, 26.3, 27.6, 28.4, 30.4, 31.8, 32.7, 34.4, 35.5, 57.0, 73.9, 74.8, 85.7, 125.6, 126.6, 130.1, 132.7, 134.0, 136.2, 175.6; HRMS (FAB): m/z calcd for $\text{C}_{21}\text{H}_{34}\text{O}_4\text{Na}$ ($[\text{M}+\text{Na}]^+$) 373.2355, found 373.2354.

4.16. (5Z,8R,9E,11S,12S,14Z)-11-[(R/S)-1-Ethoxyethoxy]-8-hydroxy-12-(4-methoxyphenyl)methoxy-5,9,14-icosatrienoic acid (19c)

To a stirred mixture of **4** (134 mg, 0.222 mmol) and ethyl vinyl ether (32.0 μL , 0.334 mmol) in CH_2Cl_2 (2 mL) was added PPTS (7.4 mg, 0.029 mmol) at room temperature. After being stirred overnight, the solution was poured into saturated aq NaHCO_3 and extracted with CH_2Cl_2 . The extract was washed with brine, dried (MgSO_4), and concentrated in vacuo to give crude **19a**, which was dissolved in THF (0.7 mL). To the solution was added a solution of TBAF (1 M in THF, 0.70 mL, 0.70 mmol) at 0 °C, and the mixture was stirred for 1 h. The mixture was warmed to room temperature, stirred for an additional 3 h, and quenched with saturated aq NH_4Cl . The mixture was extracted with Et_2O , and the extract was washed with brine, dried (MgSO_4), and concentrated in vacuo to give crude **19b**, which was then taken up in a THF/ H_2O (3:1, 4.4 mL). To the solution was added $\text{LiOH}\cdot\text{H}_2\text{O}$ (37.6 mg, 0.896 mmol) at room temperature and the mixture was stirred overnight at 40 °C. The mixture was quenched with saturated aq NH_4Cl and extracted with CH_2Cl_2 . The extract was washed with brine, dried (Na_2SO_4), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/ $\text{EtOAc}=1:1$) to give **19c** (as a ca. 3:2 diastereomeric mixture, 115 mg, 94% from **4**) as a colorless oil. $[\alpha]_D^{25} +11.2$ (c 1.57, CHCl_3); IR: ν_{\max} 1709 (m), 1514 (m), 1246 (s), 1037 (s); ^1H NMR: δ 0.878 (0.6 \times 3H, t, $J=6.8$ Hz), 0.884 (0.4 \times 3H, t, $J=6.8$ Hz), 1.15 (0.6 \times 3H, t, $J=7.0$ Hz), 1.16 (0.4 \times 3H, t, $J=7.0$ Hz), 1.22–1.37 (9H, m), 1.71 (2H, quint, $J=7.2$ Hz), 2.00 (2H, q, $J=6.4$ Hz), 2.12 (2H, q, $J=7.2$ Hz), 2.16–2.23 (1H, m), 2.25–2.37 (5H, m), 3.37–3.68 (3H, m), 3.80 (3H, s), 4.05–4.21 (2H, m), 4.52–4.61 (2H, m), 4.73 (0.6 \times 1H, q, $J=5.3$ Hz), 4.75 (0.4 \times 1H, q, $J=5.3$ Hz), 5.40–5.56 (4H, m), 5.61–5.76 (2H, m), 6.85 (0.6 \times 2H, d, $J=8.7$ Hz), 6.86 (0.4 \times 2H, d, $J=8.7$ Hz), 7.26 (2H, d, $J=8.7$ Hz); ^{13}C NMR: δ 14.2, 15.3/15.4, 20.4/20.6, 22.7, 24.5, 26.7, 27.50/27.53, 28.5/28.6, 29.4, 31.0/33.3, 31.7, 35.2/35.3, 55.3, 59.2/61.0, 71.7/71.8, 72.6, 77.4/77.7, 81.2/81.4, 97.4/100.0, 113.69/113.74 (2C), 125.8/125.9, 126.0, 128.0/128.8, 129.6/129.7 (2C), 130.8/130.9, 131.75/131.78, 131.84/131.9, 134.9/136.2, 159.19/159.21, 178.5/178.6; HRMS (FAB): m/z calcd for $\text{C}_{32}\text{H}_{50}\text{O}_7\text{Na}$ ($[\text{M}+\text{Na}]^+$) 569.3454, found 569.3453.

4.17. (6Z,9R)-9-[(1E,3S,4S,6Z)-3-[(R/S)-1-Ethoxyethoxy]-4-(4-methoxyphenyl)methoxy-1,6-dodecadienyl]-4,5,8,9-tetrahydro-2(3H)-oxoninone (20a)

To a stirred solution of **19c** (115 mg, 0.209 mmol) and DIPEA (260 μL , 1.49 mmol) in THF (4 mL) was added 2,4,6-trichlorobenzoyl chloride (163 μL , 1.04 mmol) at 0 °C. After 30 min, the mixture was warmed to room temperature and stirred for 1.5 h. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was diluted with toluene (6 mL) and added dropwise to a solution of DMAP (638 mg, 5.23 mmol) in toluene (205 mL) at 90 °C over 8 h. After being stirred at 90 °C for an additional 1 h, the mixture was cooled to room temperature and diluted with EtOAc . The resulting solution was successively washed with saturated aq NaHCO_3 and brine, dried (MgSO_4), and concentrated in vacuo. The residue was

purified by silica gel column chromatography (hexane/ $\text{EtOAc}=10:1$) to give **20a** (97.4 mg, 88%) as a pale yellow oil. $[\alpha]_D^{25} +62.0$ (c 0.900, CHCl_3); IR: ν_{\max} 1741 (m), 1613 (w), 1513 (m), 1247 (m), 1079 (s); ^1H NMR: δ 0.88 (3H, t, $J=6.7$ Hz), 1.15 (3H, t, $J=7.0$ Hz), 1.20–1.37 (9H, m), 1.74–1.86 (1H, m), 1.96–2.13 (5H, m), 2.13–2.54 (6H, m), 3.36–3.53 (2H, m), 3.53–3.66 (1H, m), 3.80 (3H, s), 4.08 (0.4 \times 1H, t, $J=5.8$ Hz), 4.16–4.20 (0.6 \times 1H, m), 4.49–4.62 (2H, m), 4.70 (0.6 \times 1H, q, $J=5.4$ Hz), 4.75 (0.4 \times 1H, q, $J=5.4$ Hz), 5.24–5.31 (1H, m), 5.39–5.56 (4H, m), 5.70–5.88 (2H, m), 6.85 (0.6 \times 2H, d, $J=8.4$ Hz), 6.86 (0.4 \times 2H, d, $J=8.4$ Hz), 7.26 (2H, d, $J=8.4$ Hz); ^{13}C NMR: δ 14.2, 15.3/15.5, 20.4/20.6, 22.7, 25.4, 26.6, 27.5/27.6, 28.4/28.6, 29.4, 31.7, 33.6, 34.55/34.61, 55.3/55.4, 59.4/60.7, 72.5, 77.8, 81.0, 81.1 97.8/100.2, 113.69/113.74 (2C), 124.5, 125.6/125.8, 129.55/129.64 (2C), 130.2/130.3, 130.8/130.9, 131.5, 131.9/132.0, 135.1, 159.21/159.23, 173.8/173.9; HRMS (FAB): m/z calcd for $\text{C}_{32}\text{H}_{48}\text{O}_6\text{Na}$ ($[\text{M}+\text{Na}]^+$) 551.3349, found 551.3347.

4.18. (6Z,9R)-9-[(1E,3R,4S,6Z)-3,4-Epoxy-1,6-dodecadienyl]-4,5,8,9-tetrahydro-2(3H)-oxoninone (3)

To a stirred solution of **20a** (66.0 mg, 0.125 mmol) in EtOH (1.2 mL) was added PPTS (94.1 mg, 0.375 mmol) at room temperature. After being stirred overnight, the solution was quenched with saturated aq NaHCO_3 and extracted with CH_2Cl_2 . The extract was washed with brine, dried (MgSO_4), and concentrated in vacuo to give crude **20b**, which was dissolved in CH_2Cl_2 (1.2 mL). To the solution were successively added DIPEA (0.110 mL, 0.632 mmol), DMAP (76.3 mg, 0.625 mmol), and Ms_2O (76.2 mg, 0.437 mmol) while stirring at 0 °C. After 5 h, the solution was quenched with saturated aq NH_4Cl and extracted with CH_2Cl_2 . The extract was washed with brine, dried (Na_2SO_4), and concentrated in vacuo to give crude **20c**, which was taken up in $\text{CH}_2\text{Cl}_2/\text{pH}$ 7 phosphate buffer (10:1, 2.2 mL). To the solution was added DDQ (90.4 mg, 0.396 mmol) while stirring at 0 °C, and the mixture was stirred overnight at the same temperature. The mixture was quenched with saturated aq NaHCO_3 and extracted with CH_2Cl_2 . The extract was washed with brine, dried (Na_2SO_4), and concentrated in vacuo. The residue was roughly purified by silica gel column chromatography to remove *p*-methoxybenzaldehyde (hexane/ $\text{EtOAc}=4:1$) to give crude **20d**. The hydroxy mesylate **20d** just obtained was dissolved in MeOH (1 mL) and mixed with K_2CO_3 (17.3 mg, 0.125 mmol) while stirring at –15 °C. After 1 h, the mixture was filtered into a stirred solution of $\text{Et}_2\text{O}/\text{saturated aq NH}_4\text{Cl}$ at 0 °C and extracted with ether. The extract was washed with brine, dried (Na_2SO_4), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/ $\text{EtOAc}=8:1$) to give **3** (6.4 mg, 16% from **20a**) as a colorless oil. $[\alpha]_D^{25} +73$ (c 0.22, MeOH); IR: ν_{\max} 3011 (w), 1741 (s), 1257 (m), 1218 (m), 1136 (m); ^1H NMR (CD_3OD): δ 0.90 (3H, t, $J=6.6$ Hz), 1.26–1.41 (6H, m), 1.69–1.82 (1H, m), 1.98–2.27 (7H, m), 2.32–2.58 (4H, m), 3.11 (1H, dt, $J=4.3$, 6.4 Hz), 3.47 (1H, dd, $J=6.9$, 4.3 Hz), 5.29 (1H, dd, $J=10.9$, 5.6 Hz), 5.40 (1H, dt, $J=10.8$, 7.3 Hz), 5.45–5.56 (3H, m), 5.75 (1H, dd, $J=15.5$, 6.9 Hz), 6.03 (1H, dd, $J=15.5$, 5.7 Hz); ^{13}C NMR (CD_3OD , δ 49.00 ppm): δ 14.4, 23.7, 26.3, 27.0, 27.6, 28.4, 30.4, 32.7, 34.4, 35.4, 57.3, 59.5, 73.8, 124.7, 125.5, 127.3, 133.8, 135.2, 136.2, 175.6; HRMS (FAB): m/z calcd for $\text{C}_{20}\text{H}_{30}\text{O}_3\text{Na}$ ($[\text{M}+\text{Na}]^+$) 341.2093, found 341.2092.

4.19. Conversion of topsentolide **A₂ (**3**) into topsentolide **C**₂ (**2**)**

To a stirred solution of **3** (1.5 mg, 4.7 μmol) in MeOH (1 mL) was added a solution of HCl in MeOH (0.125 M, 5.0 μL , 0.63 μmol) at 0 °C. The mixture was stirred at 0 °C for 1 h and then at room temperature for an additional 1 h. To the mixture was added again the methanolic HCl solution (10 μL , 1.3 μmol) at room temperature and the resulting solution was stirred for 1.5 h. The mixture was

quenched with saturated aq NaHCO₃ and extracted with ether. The extract was washed with brine, dried (Na₂SO₄), and concentrated in vacuo to give **2** (1.7 mg, quant) as a virtually pure compound, as judged by its ¹H and ¹³C NMR spectra.

Acknowledgements

This work was financially supported, in part, by a Grant-in-Aid for Scientific Research (B) from the MEXT (No. 24658105).

Supplementary data

¹H and ¹³C NMR spectra of **2**, **3**, key synthetic intermediates, and the crude ring-opening product of **3**. Supplementary data associated with this article can be found in the online version, at <http://dx.doi.org/10.1016/j.tet.2014.04.040>. These data include MOL file and InChIKeys of the most important compounds described in this article.

References and notes

1. Luo, X.; Li, F.; Hong, J.; Lee, C.-O.; Sim, C. J.; Im, K. S.; Jung, J. H. *J. Nat. Prod.* **2006**, *69*, 567–571.
2. For recent reviews on oxylipins, see: (a) Andreou, A.; Brodhun, F.; Feussner, I. *Prog. Lipid Res.* **2009**, *48*, 148–170; (b) Böttcher, C.; Pollmann, S. *FEBS J.* **2009**, *276*, 4693–4704; (c) Brodhun, F.; Feussner, I. *FEBS J.* **2011**, *278*, 1047–1063.
3. Kobayashi, M.; Ishigami, K.; Watanabe, H. *Tetrahedron Lett.* **2010**, *51*, 2762–2764.
4. Sreedhar, E.; Venkanna, A.; Chandramouli, N.; Babu, K. S.; Rao, J. M. *Eur. J. Org. Chem.* **2011**, 1078–1083.
5. (a) Fernandes, R. A.; Kattanguru, P. *Tetrahedron Lett.* **2011**, *52*, 1788–1790; (b) Fernandes, R. A.; Kattanguru, P. *Tetrahedron: Asymmetry* **2011**, *22*, 1930–1935.
6. Wetzel, I.; Krauss, J.; Bracher, F. *Lett. Org. Chem.* **2012**, *9*, 169–174.
7. Towada, R.; Kurashina, Y.; Kuwahara, S. *Tetrahedron Lett.* **2013**, *54*, 6878–6881.
8. (a) Miura, A.; Kuwahara, S. *Tetrahedron* **2009**, *65*, 3364–3368; (b) Kurashina, Y.; Miura, A.; Enomoto, M.; Kuwahara, S. *Tetrahedron* **2011**, *67*, 1649–1653; (c) Kurashina, Y.; Kuwahara, S. *Biosci. Biotechnol. Biochem.* **2012**, *76*, 605–607.
9. The preparation of the enantiomer of **5** was previously communicated in Ref. 7.
10. (a) Williams, D. R.; Plummer, S. V.; Patnaik, S. *Tetrahedron* **2011**, *67*, 5083–5097; (b) Sneddon, H. F.; Gaunt, M. J.; Ley, S. V. *Org. Lett.* **2003**, *5*, 1147–1150.
11. Mikkilineni, A. B.; Kumar, P.; Abushanab, E. *J. Org. Chem.* **1988**, *53*, 6005–6009.
12. Ruiz, P.; Murga, J.; Carda, M.; Marco, J. A. *J. Org. Chem.* **2005**, *70*, 713–716.
13. Askin, D.; Reamer, R. A.; Joe, D.; Volante, R. P.; Shinkai, I. *Tetrahedron Lett.* **1989**, *30*, 6121–6124.
14. Singh, J.; Kaur, J.; Nayyar, S.; Bhandari, M.; Kad, G. L. *J. Indian Chem., Sect. B: Org. Chem. Incl. Med. Chem.* **2001**, *40B*, 386–390.
15. The preparation of **6** was reported in our short communication (Ref. 7) without experimental details.
16. Blanchette, M. A.; Choy, W.; Davis, J. T.; Essenfeld, A. P.; Masamune, S.; Roush, W. R.; Sakai, T. *Tetrahedron Lett.* **1984**, *25*, 2183–2186.
17. Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. *Bull. Chem. Soc. Jpn.* **1979**, *52*, 1989–1993.
18. No signal assignable to 11-*epi*-**2**,⁷ the product formed by the attack of MeOH at the C11 position of **3** with retention of configuration, was observed in the ¹H and ¹³C NMR spectra of the crude reaction product. This means that the epoxide ring-opening reaction took place with complete (or almost complete) inversion of configuration, which might be in accord with the fact that 11-*epi*-**2** was not isolated from the MeOH extract of *Topsentia* sp.